Published in Am J Surg Pathol on March 01, 2016
Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi. Mod Pathol (2016) 0.79
Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway. Oncotarget (2016) 0.79
Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment. F1000Res (2016) 0.75
Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44. PLoS One (2017) 0.75
Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi. Nat Commun (2017) 0.75
A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth. Angiogenesis (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Magnetic domain-wall racetrack memory. Science (2008) 8.24
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med (2002) 5.58
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Chiral spin torque at magnetic domain walls. Nat Nanotechnol (2013) 2.98
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94
Telemedical wound care using a new generation of mobile telephones: a feasibility study. Arch Dermatol (2005) 2.91
Dermoscopic examination of nail pigmentation. Arch Dermatol (2002) 2.83
Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol (2003) 2.83
Current-controlled magnetic domain-wall nanowire shift register. Science (2008) 2.68
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med (2007) 2.41
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
Dependence of current and field driven depinning of domain walls on their structure and chirality in permalloy nanowires. Phys Rev Lett (2006) 2.11
Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol (2011) 2.03
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol (2011) 1.92
Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol (2009) 1.87
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Defining early mycosis fungoides. J Am Acad Dermatol (2005) 1.78
Diagnosis and management of nail pigmentations. J Am Acad Dermatol (2007) 1.73
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
Hemophilia A induced by ipilimumab. N Engl J Med (2011) 1.55
Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer (2010) 1.54
Time required for a complete skin examination with and without dermoscopy: a prospective, randomized multicenter study. Arch Dermatol (2008) 1.53
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Arch Dermatol (2008) 1.51
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol (2005) 1.51
Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma. J Cutan Pathol (2008) 1.50
Brain magnetic resonance imaging in patients with Cowden syndrome. Medicine (Baltimore) (2005) 1.50
Sarcoidosis and melanoma: a referral center study of 1,199 cases. Dermatology (2009) 1.49
Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol (2013) 1.49
Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol (2008) 1.47
Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Arch Dermatol (2008) 1.45
The furrow ink test: a clue for the dermoscopic diagnosis of acral melanoma vs nevus. Arch Dermatol (2008) 1.44
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol (2002) 1.40
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie (2012) 1.39
[Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma]. Med Sci (Paris) (2011) 1.38
mda-9/Syntenin: a positive regulator of melanoma metastasis. Cancer Res (2005) 1.35
Frequency of dermoscopic nevus subtypes by age and body site: a cross-sectional study. Arch Dermatol (2011) 1.34
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol (2003) 1.30
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol (2009) 1.26
Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation (2003) 1.26
A UV-sensitive syndrome patient with a specific CSA mutation reveals separable roles for CSA in response to UV and oxidative DNA damage. Proc Natl Acad Sci U S A (2009) 1.26
Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget (2013) 1.24
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]. Bull Cancer (2002) 1.24
Dermoscopic Features of Onychomatricoma: A Study of 34 Cases. Dermatology (2015) 1.23
Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res (2008) 1.21
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol (2011) 1.20
Rituximab therapy for HIV-associated Castleman disease. Blood (2003) 1.16
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med (2013) 1.15
Enhanced stochasticity of domain wall motion in magnetic racetracks due to dynamic pinning. Nat Commun (2010) 1.15
Accuracy in melanoma detection: a 10-year multicenter survey. J Am Acad Dermatol (2011) 1.15
Current driven domain wall velocities exceeding the spin angular momentum transfer rate in permalloy nanowires. Phys Rev Lett (2007) 1.15
Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res (2012) 1.14
Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J Med Genet (2011) 1.14
Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 1.14
Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol (2005) 1.13
MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J Exp Med (2008) 1.13
Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas. Oncogene (2004) 1.10
Survival and prognostic factors in a series of adults with medulloblastomas. J Neurosurg (2009) 1.10
Gluten intolerance and skin diseases. Eur J Dermatol (2006) 1.08
Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer (2010) 1.08
Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol (2013) 1.06
Imaging of the most frequent superficial soft-tissue sarcomas. Skeletal Radiol (2010) 1.05
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04
Subungual blue nevus. J Am Acad Dermatol (2003) 1.04
Kidney injuries related to ipilimumab. Invest New Drugs (2014) 1.03
Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol (2013) 1.02
Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma. Melanoma Res (2015) 1.01
The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Dermatol (2007) 1.01
Fetal microchimeric cells participate in tumour angiogenesis in melanomas occurring during pregnancy. Am J Pathol (2009) 1.00
Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol (2014) 0.99
A 4-gene signature associated with clinical outcome in high-grade gliomas. Clin Cancer Res (2011) 0.99
Dermoscopic evaluation of nodular melanoma. JAMA Dermatol (2013) 0.99